Transformative therapeutics for drug resistant and aggressive cancers by targetting the Epitheilal-Mesenchymal Transition/Cancer Stem Cells
CELLSELECT ™
The Path to BerGenBio’s Product Engine
EMT/CSC Targets
Targeting hard-to-treat cancers
News
- 08.14.2012Former KuDOS CEO Barrie Ward appointed to BerGenBio board
- 01.04.2012BerGenBio completes $9 million Series A financing for first in class oncology therapeutics